NuGenerex Immuno-Oncology Announces Shareholder Conference Call on Thursday August 27th, 2020 at 9:30 AM to Provide Details on Impending Corporate Initiatives
August 04, 2020 09:00 ET
|
Generex Biotechnology Corp.
Ii-Key-SARS-CoV-2 vaccine progressIi-Key-H1 Swine flu vaccine opportunitySEC Filings and plans for listing on a national exchange MIRAMAR, Fla., Aug. 04, 2020 (GLOBE NEWSWIRE) -- NuGenerex...
Generex Biotechnology Announces Shareholder Conference Call on Wednesday August 26th, 2020 at 9:30 AM to Provide Details on Impending Corporate Initiatives
August 03, 2020 09:00 ET
|
Generex Biotechnology Corp.
Telemedicine & Remote Patient Monitoring PartnershipArizona MSO/HMO updateAltuCell acquisition update MIRAMAR, Fla., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation...
Generex Biotechnology Announces That FDA has Accepted the Pre-IND Briefing Package for the Company’s Ii-Key-SARS-CoV-2 Vaccine and Will Provide a Written Response by August 24, 2020
July 27, 2020 09:15 ET
|
Generex Biotechnology Corp.
MIRAMAR, Fla., July 27, 2020 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) today announced that the FDA has...
Generex Biotechnology Files Pre-IND Briefing Package with FDA for Ii-Key-SARS-CoV-2 Peptide Vaccine Against the COVID-19 Pandemic
July 20, 2020 09:00 ET
|
Generex Biotechnology Corp.
Submitted Pre-IND briefing package outlining proposed clinical development program for Ii-Key-SARS-CoV-2 prophylactic peptide vaccine against the coronavirus pandemicFinal protocol submitted with...
NuGenerex Immuno-Oncology Closes $50 Million Financing Facility
July 15, 2020 09:30 ET
|
Generex Biotechnology Corp.
NuGenerex Immuno-Oncology, a 91% subsidiary of Generex Biotechnology Corporation (GNBT:OTCQB) announces first financing in preparation for public listingNuGenerex Immuno-Oncology is developing...
Generex Biotechnology Announces Corporate Update and Investor Conference Call: NuGenerex Immuno-Oncology Today Friday July 10, 2020 at 4:15 PM
July 10, 2020 08:30 ET
|
Generex Biotechnology Corp.
MIRAMAR, Fla., July 10, 2020 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) today announced call-in details for today’s investor conference call on Friday July...
NuGenerex Immuno-Oncology Announces Plans to Address the New Emerging Pandemic Threat from G4 EA H1N1 Swine Influenza Virus Using Ii-Key-H1 Peptide Vaccine
July 02, 2020 09:00 ET
|
Generex Biotechnology Corp.
NGIO has previously developed Ii-Key-H1 peptides for vaccines against epitopes to 2009 Swine Flu and 2004 Bird Flu with positive Phase I clinical safety and immunologic data for Ii-Key-H1 peptide...
NuGenerex Immuno-Oncology Announces Board of Directors
July 01, 2020 09:00 ET
|
Generex Biotechnology Corp.
- Renowned leaders in biotechnology, pharmaceuticals, oncology, operations and finance to provide guidance to management team- NuGenerex Immuno-Oncology (NGIO) is focused on modulation of the immune...
NuGenerex Immuno-Oncology Announces Shareholder Conference Call July 10, 2020 at 4:15 PM
June 26, 2020 09:00 ET
|
Generex Biotechnology Corp.
NuGenerex Immuno-Oncology (NGIO) is focused on modulation of the immune system to develop Ii-Key peptide vaccines for the treatment and prevention of cancer and infectious diseasesNGIO is now a...
Generex Subsidiary NGIO Advances COVID-19 Vaccine Program with the Manufacturing of Patent-Pending Ii-Key-SARS-CoV-2 Peptides
May 22, 2020 09:45 ET
|
Generex Biotechnology Corporation
NuGenerex Immuno-Oncology (NGIO) is focused on modulation of the immune system to develop Ii-Key peptide vaccines for the treatment and prevention of cancer and infectious diseasesNGIO advancing...